Early Intervention with 3BNC117 and Romidepsin at Antiretroviral Treatment Initiation in People with HIV-1: A Phase Ib/IIa, Randomized Trial

The authors investigated whether early intervention in newly diagnosed people with HIV-1 with a monoclonal anti-HIV-1 antibody with a CD4-binding site, 3BNC117, followed by a histone deacetylase inhibitor, romidepsin, shortly after antiretroviral therapy initiation altered the course of HIV-1 infection.